WC
DMII

Wealthspring Capital’s Drugs Made In America Acquisition II Corp DMII Stock Holding History

Wealthspring Capital’s Portfolio DMII Stock Details DMII Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.03M Sell
400,440
-2,230
-0.6% -$22.4K 0.9% 44
2026
Q1 		$4.01M Sell
402,670
-6,280
-2% -$62.6K 0.95% 41
2025
Q4 		$4.05M Buy
+408,950
New +$4.04M 0.96% 40

Other funds holding DMII

CCM
Context Capital Management Lajolla, California $5.15B AUM 1.28% 1-Year Est. Return
MCS
Mercuria Capital Strategies Houston, Texas $163M AUM 258.7% 1-Year Est. Return
COPPSERS
Commonwealth of Pennsylvania Public School Employees Retirement System Harrisburg, Pennsylvania $20.6B AUM 37.37% 1-Year Est. Return
DAM
Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return
AA
ABC Arbitrage Paris, France $926M AUM 45.9% 1-Year Est. Return
TCM
Tuttle Capital Management Riverside, Connecticut $148M AUM 64.07% 1-Year Est. Return

Wealthspring Capital's DMII Position: Q2 2026 in Review

Wealthspring Capital reduced its Drugs Made In America Acquisition II Corp (DMII) stake by 0.55% in Q2 2026, selling an estimated $22.4K and leaving 400,440 shares worth $4.03M. The position accounts for 0.9% of the portfolio, ranked #44.

Wealthspring Capital first reported a position in DMII in Q4 2025 and has held it in 3 quarters since. The position peaked at $4.05M in Q4 2025. 7 funds tracked by Wall St. Rank hold DMII as of Q2 2026.

  • Wealthspring Capital held 400,440 shares of Drugs Made In America Acquisition II Corp worth $4.03M as of Q2 2026.
  • Wealthspring Capital sold 2,230 Drugs Made In America Acquisition II Corp shares in Q2 2026, an estimated $22.4K.
  • Drugs Made In America Acquisition II Corp made up 0.9% of Wealthspring Capital's portfolio in Q2 2026, its #44 holding.
  • Wealthspring Capital first reported a position in Drugs Made In America Acquisition II Corp in Q4 2025 and has held it in 3 quarters since.
  • Wealthspring Capital's Drugs Made In America Acquisition II Corp position peaked at $4.05M in Q4 2025.
  • 7 funds tracked by Wall St. Rank held Drugs Made In America Acquisition II Corp as of Q2 2026.

Based on Wealthspring Capital's 13F filing for Q2 2026, filed 15 Jul 2026.